Skip to content

Study · Randomized controlled trial · n = 24 · 2019

7 results

Efficacy and safety of lanreotide in postoperative dumping syndrome: A Phase II randomised and placebo-controlled study.

Wauters L, Arts J, Caenepeel P, Holvoet L, Tack J, Bisschops R, Vanuytsel T

United European gastroenterology journal27 Jun 2019Cited by 15 (Europe PMC)

PMID31662863 (opens in a new tab)PMCIDPMC6794701 (opens in a new tab)DOI10.1177/2050640619862166 (opens in a new tab)PepBankPUB-31662863
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In adults with postoperative dumping syndrome, 44 adverse events occurred on lanreotide versus 37 on placebo (p > 0.05).

    In plain wordsIn adults with postoperative dumping syndrome, adverse event counts did not differ significantly between lanreotide and placebo.

    Peptide
    Lanreotide
    Outcome
    No significant changeAdverse events
    Study

    n = 24

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    90 mg monthly · Three monthly injectionsAs given in this study (human).

    Measurements

    adverse events
    44 events
    lanreotide
    adverse events
    37 events
    placebo

    Source sentences

    Summary
    Of the 81 reported adverse events, 44 occurred on LAN compared to 37 on placebo (p > 0.05), with seven serious adverse events on LAN.
    2 context sentences
    Summary · context
    We performed a double-blind, randomised and placebo-controlled crossover study of LAN Autogel® 90 mg in postoperative dumping.
    Summary · context
    Adults with a positive prolonged oral glucose tolerance test or spontaneous hypoglycaemia and total dumping score (DS) ≥ 10 despite dietary measures were treated with three monthly injections of LAN or placebo in a randomised crossover fashion with an eight-week wash-out period.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with postoperative dumping syndrome, pooled total dumping score after three injections was lower than baseline with lanreotide (median 14 versus 22, p = 0.03) but not with placebo (median 20 versus 23, p = 0.15).

    In plain wordsIn adults with postoperative dumping syndrome, total symptom scores fell versus baseline after lanreotide but not after placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseTotal dumping score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Dumping Symptoms · Gastrointestinal
    Studied dose
    90 mg monthly · Three monthly injectionsAs given in this study (human).

    Measurements

    Pooled total dumping score
    14
    after lanreotide, IQR 11.5-23
    Pooled total dumping score
    22
    baseline for lanreotide, IQR 16-27
    P value, lanreotide versus baseline
    0.03
    Pooled total dumping score
    20
    after placebo, IQR 15-27
    Pooled total dumping score
    23
    baseline for placebo, IQR 13-29
    P value, placebo versus baseline
    0.15

    Source sentences

    Summary
    Pooled DS after three injections were lower compared to baseline after LAN (median=14 (interquartile range (IQR) 11.5-23) vs. median = 22 (IQR 16-27); p = 0.03) but not placebo (median = 20 (IQR 15-27) vs. median = 23 (IQR 13-29); p = 0.15).
    2 context sentences
    Summary · context
    We performed a double-blind, randomised and placebo-controlled crossover study of LAN Autogel® 90 mg in postoperative dumping.
    Summary · context
    Adults with a positive prolonged oral glucose tolerance test or spontaneous hypoglycaemia and total dumping score (DS) ≥ 10 despite dietary measures were treated with three monthly injections of LAN or placebo in a randomised crossover fashion with an eight-week wash-out period.
  3. 03HumanNon-randomized trialSafety outcome

    In adults with postoperative dumping syndrome, seven serious adverse events occurred on lanreotide.

    In plain wordsIn adults with postoperative dumping syndrome, seven serious adverse events occurred on lanreotide.

    Peptide
    Lanreotide
    Outcome
    Not applicableSerious adverse events
    Study

    n = 24

    Analysis
    Secondary
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    90 mg monthly · Three monthly injectionsAs given in this study (human).

    Measurements

    serious adverse events
    7 events
    lanreotide

    Source sentences

    Summary
    Of the 81 reported adverse events, 44 occurred on LAN compared to 37 on placebo (p > 0.05), with seven serious adverse events on LAN.
    2 context sentences
    Summary · context
    We performed a double-blind, randomised and placebo-controlled crossover study of LAN Autogel® 90 mg in postoperative dumping.
    Summary · context
    Adults with a positive prolonged oral glucose tolerance test or spontaneous hypoglycaemia and total dumping score (DS) ≥ 10 despite dietary measures were treated with three monthly injections of LAN or placebo in a randomised crossover fashion with an eight-week wash-out period.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with postoperative dumping syndrome, early score decreased from median 12 to 7.5 after lanreotide (p = 0.03).

    In plain wordsIn adults with postoperative dumping syndrome, lanreotide reduced early symptom scores versus baseline.

    Peptide
    Lanreotide
    Outcome
    DecreaseEarly dumping score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Dumping Symptoms · Gastrointestinal
    Studied dose
    90 mg monthly · Three monthly injectionsAs given in this study (human).

    Measurements

    Early dumping score
    7.5
    median, IQR 4.5-13
    Early dumping score
    12
    median, IQR 9-16, baseline
    P value for early dumping score
    0.03

    Source sentences

    Summary
    Improvement of early (median = 7.5 (IQR 4.5-13) vs. median = 12 (IQR 9-16); p = 0.03) but not late (median = 7 (IQR 6-10.3) vs. median = 9 (IQR 6-13); p = 0.26) DS was seen.
    2 context sentences
    Summary · context
    We performed a double-blind, randomised and placebo-controlled crossover study of LAN Autogel® 90 mg in postoperative dumping.
    Summary · context
    Adults with a positive prolonged oral glucose tolerance test or spontaneous hypoglycaemia and total dumping score (DS) ≥ 10 despite dietary measures were treated with three monthly injections of LAN or placebo in a randomised crossover fashion with an eight-week wash-out period.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with postoperative dumping syndrome, late score did not significantly change after lanreotide (median 9 to 7, p = 0.26).

    In plain wordsIn adults with postoperative dumping syndrome, lanreotide did not significantly change late symptom scores versus baseline.

    Peptide
    Lanreotide
    Outcome
    No significant changeLate dumping score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Dumping Symptoms · Gastrointestinal
    Studied dose
    90 mg monthly · Three monthly injectionsAs given in this study (human).

    Measurements

    Late dumping score
    7
    median, IQR 6-10.3
    Late dumping score
    9
    median, IQR 6-13, baseline
    P value for late dumping score
    0.26

    Source sentences

    Summary
    Improvement of early (median = 7.5 (IQR 4.5-13) vs. median = 12 (IQR 9-16); p = 0.03) but not late (median = 7 (IQR 6-10.3) vs. median = 9 (IQR 6-13); p = 0.26) DS was seen.
    2 context sentences
    Summary · context
    We performed a double-blind, randomised and placebo-controlled crossover study of LAN Autogel® 90 mg in postoperative dumping.
    Summary · context
    Adults with a positive prolonged oral glucose tolerance test or spontaneous hypoglycaemia and total dumping score (DS) ≥ 10 despite dietary measures were treated with three monthly injections of LAN or placebo in a randomised crossover fashion with an eight-week wash-out period.
  6. 06HumanObservational studyEfficacy outcome

    In postoperative dumping syndrome, treatment assessment correlated inversely with dumping score change (r = -0.69, p = 0.004).

    In plain wordsIn adults with postoperative dumping syndrome, treatment assessment was inversely linked to the change in symptom scores.

    Peptide
    Lanreotide
    Outcome
    Not applicableTreatment assessment correlation
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Dumping Symptoms · Gastrointestinal
    Studied dose
    90 mg monthly · Three monthly injectionsAs given in this study (human).

    Measurements

    correlation coefficient (treatment assessment vs change in DS)
    −0.69 r
    overall treatment assessment and change in total dumping score

    Source sentences

    Summary
    Overall treatment assessment correlated with change in DS (r = -0.69, p = 0.004).
    2 context sentences
    Summary · context
    We performed a double-blind, randomised and placebo-controlled crossover study of LAN Autogel® 90 mg in postoperative dumping.
    Summary · context
    Adults with a positive prolonged oral glucose tolerance test or spontaneous hypoglycaemia and total dumping score (DS) ≥ 10 despite dietary measures were treated with three monthly injections of LAN or placebo in a randomised crossover fashion with an eight-week wash-out period.
  7. 07HumanObservational studyEfficacy outcome

    In adults with postoperative dumping syndrome, symptom improvement was not associated with quality-of-life changes.

    In plain wordsIn adults with postoperative dumping syndrome, symptom improvement was not linked to quality-of-life changes.

    Peptide
    Lanreotide
    Outcome
    No significant changeQuality of life association
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Quality of life · Gastrointestinal
    Studied dose
    90 mg monthly · Three monthly injectionsAs given in this study (human).

    Source sentences

    Summary
    Symptom improvement was not associated with changes in quality of life.
    2 context sentences
    Summary · context
    We performed a double-blind, randomised and placebo-controlled crossover study of LAN Autogel® 90 mg in postoperative dumping.
    Summary · context
    Adults with a positive prolonged oral glucose tolerance test or spontaneous hypoglycaemia and total dumping score (DS) ≥ 10 despite dietary measures were treated with three monthly injections of LAN or placebo in a randomised crossover fashion with an eight-week wash-out period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.